CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Contraception - Management
What is the levonorgestrel-releasing intrauterine system (IUS)?
- The levonorgestrel intrauterine system (IUS) is a small polyethylene T-shaped frame with a levonorgestrel reservoir around the vertical stem.
- After insertion into the uterine cavity, the IUS releases 20 micrograms of levonorgestrel (a progestogen) per day into the uterus.
- One levonorgestrel-releasing IUS is licensed in the UK; it is marketed as the Mirena® IUS.
- Mirena® is effective for at least 5 years and is licensed for use for:
- Contraception.
- Idiopathic menorrhagia. It can be used in women with idiopathic menorrhagia requiring (reversible) contraception.
- Protection from endometrial hyperplasia during oestrogen replacement therapy.
[ABPI Medicines Compendium, 2004d; BNF 53, 2007]
© NHS Institute for Innovation and Improvement